This is a demo store. No orders will be fulfilled.

Cevostamab (anti-CD3&FCRL5) - Primary antibody, specific to CD3E & FCRL5, Human IgG1

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Cynomolgus monkey,Human
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
In stock
Item Number
Ab182817
Grouped product items
SKU Size
Availability
Price Qty
Ab182817-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$69.90
Ab182817-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$349.90
Ab182817-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$899.90
Ab182817-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,439.90

Purity≥90% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Cevostamab (anti-CD3&FCRL5) - Primary antibody, specific to CD3E & FCRL5, Human IgG1
Synonyms BXMAS1 antibody | CD307 antigen antibody | CD307e antibody | Fc receptor homolog 5 antibody | Fc receptor like 5 antibody | Fc receptor-like protein 5 antibody | FcR-like protein 5 antibody | FcRH5 antibody | FcRL5 antibody | FCRL5_HUMAN antibody | Immuno
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥90%(SDS-PAGE&SEC-HPLC), See COA
Biochemical and Physiological Mechanisms CD3: The CD3 complex mediates signal transduction. FCRL5: May be involved in B-cell development and differentiation in peripheral lymphoid organs and may be useful markers of B-cell stages. May have an immunoregulatory role in marginal zone B-cells.
Host species Human
Specificity CD3E & FCRL5
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Product Description

Cevostamab (anti-CD3&FCRL5) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab (anti-CD3&FCRL5) facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells.

Product Properties

Isotype Human IgG1
Light Chain Type kappa
SDS-PAGE 146.19 kDa
Purification Method Protein A purified
Shape Liquid
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 2249888-53-5

Associated Targets(Human)

CD3E Tclin T-cell surface glycoprotein CD3 epsilon chain (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
FCRL5 Tbio Fc receptor-like protein 5 (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Images

Cevostamab (anti-CD3&FCRL5) (Ab182817) - Flow Cytometry
Flow Cytometry analysis of huCD3e-Jurkat cells labelling CD3&FCRL5 (red) with Cevostamab (anti-CD3&FCRL5) (Ab182817) at 1×10⁵ cell/well, with the EC₅₀ is 729.0 ng/mL.

Cevostamab (anti-CD3&FCRL5) (Ab182817) - SEC
The purity of Cevostamab (anti-CD3&FCRL5) (Ab182817) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.